India, June 29 -- AstraZeneca (AZN), a pharmaceutical company, on Monday reported the recommendation for approval of Datroway in the European Union for the treatment of metastatic triple-negative breast cancer (TNBC).
Datroway is a TROP2-directed DXd antibody drug conjugate (ADC) that was developed by Daiichi Sankyo, and is currently being jointly developed by AstraZeneca and Daiichi. The drug targets TROP2, which is a protein broadly expressed in several solid tumors and is associated with increased tumor progression and poor survival in patients with breast cancer. Datroway received FDA approval in treating HR+/HER- breast cancer in 2025.
The Committee for Medicinal Products for Human Use (CHMP) provided the positive opinion to the Euro...